A longitudinal poll conducted by the Annenberg Public Policy Center from April 2021 to August 2026 shows Americans’ confidence in their personal healthcare providers to inform them about matters of public health remains high. 

In August 2026, 87% of poll respondents say they are confident that their doctor, nurse, or other primary healthcare provider is providing trustworthy information about matters of public health, statistically unchanged from 88% in September 2024, the policy center said. 

But confidence in the U.S. Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), and the National Institutes of Health (NIH) has dropped precipitously since February 2025, when Robert F. Kennedy Jr. was named head of the Department of Health and Human Services. Kennedy has said on numerous occasions that his goal is to “restore faith” in federal health agencies.
 

Only 59% say they are confident in FDA 

A total of 61% expressed confidence in the CDC as of August 2026, significantly below the 72% who expressed confidence in the CDC in September 2024. Confidence in the FDA is 59% in August 2026, significantly below the 73% expressing confidence in September 2024. Confidence in the NIH went from 74% in September 2024 to 61% in August 2026.

“We don’t see evidence in our data that the Trump administration is restoring trust in the federal health agencies,” Laura A. Gibson, an APPC research analyst, said in a press release.

The survey was based on responses from 1,904 adults and has an estimated margin of sampling error of ±3.2 percentage points at the 95% confidence level.
 

A study published last week in Obstetrics & Gynecology found no significant link between long COVID and preterm birth or several other adverse pregnancy outcomes but did uncover an association with hypertensive disorders of pregnancy.

Researchers from University of Utah Heath led the analysis of data on female COVID-19 survivors enrolled in the Researching COVID to Enhance Recovery (RECOVER) study from October 2021 to January 2024. Participants had completed at least one symptom survey and were classified as having likely or suspected long COVID before or during pregnancy.

The primary outcome was preterm birth (before 37 weeks’ gestation), and secondary outcomes were hypertensive disorders of pregnancy, cesarean delivery, neonatal intensive care unit (NICU) admission, and small-for-gestational-age birth weight (below the 10th percentile). 

Long COVID and adverse social determinants of health 

Of 603 participants, 19.6% likely had long COVID before or during pregnancy. These women were more likely to have certain adverse social determinants of health (difficulty covering expenses and paying bills, food insecurity, cost-related missed care, medical discrimination) and higher pre-pregnancy body mass index (BMI) than those with suspected long COVID. 

The association with hypertensive disorders of pregnancy in the average treatment effect among the treated analysis highlights the need for further research.

The primary treatment-effect analysis identified no link between likely long COVID and preterm delivery (adjusted outcome rate, 8.1% exposed vs 9.6% unexposed; absolute risk reduction [ARR], 0.82) or secondary outcomes. 

In the treated sensitivity analyses, probable long COVID was similarly not tied to preterm delivery (ARR, 1.11) but was associated with an increased risk of hypertensive disorders of pregnancy (adjusted outcome rate, 39.0% exposed vs 25.9% unexposed; ARR, 1.51) but not with other secondary outcomes.

“A classification of likely Long COVID was not significantly associated with preterm birth or several other adverse pregnancy outcomes,” the study authors wrote. “However, the association with hypertensive disorders of pregnancy in the average treatment effect among the treated analysis highlights the need for further research.”

Japanese drugmaker Shionogi announced last week that the US government has ordered $37 million worth of the antibiotic ceferidocol to support national preparedness.

The Biomedical Advanced Research and Development Authority’s (BARDA’s) Project BioShield exercised the $36.9 million procurement option on the antibiotic as a critical countermeasure against difficult-to-treat gram-negative bacterial infections and pathogens that could pose a biosecurity threat. 

Marketed under the brand name Fetroja, cefiderocol is a siderophore cephalosporin antibiotic with a novel method of penetrating the tough outer membrane of gram-negative bacteria and an ability to overcome resistance mechanisms used by bacteria to evade antibiotics. 

Potential treatment for biothreats

Cefiderocol was approved by the US Food and Drug Administration for treating complicated urinary tract infections and hospital-acquired and ventilator-associated bacterial pneumonia in adults. It’s since become a valued option for difficult-to-treat multidrug-resistant infections.

The order is the first of several procurement options under a contract signed in April between BARDA and Shionogi that’s worth up to $482 million. The contract includes plans to develop a US manufacturing site for cefiderocol, expand its use in children with pneumonia, and study its potential to treat infections caused by Yersinia pestis, the bacterium that causes plague, and Burkholderia pseudomallei, which causes melioidosis. 

Both pathogens occur naturally in certain parts of the world and have the potential to be used as weapons in a biological attack.